[Association between angiotensin converting enzyme I/D polymorphism and high-sensitivity C-reactive protein in type 2 diabetic patients with atherosclerosis treated with ramipril].
OBJECTIVE
To explore the relationship between angiotensin converting enzyme (ACE) (I/D) gene polymorphism and the level of high-sensitivity C-reactive protein (hsCRP) in type 2 diabetic patients with atherosclerosis treated with ramipril.


METHODS
A total of 118 in type 2 diabetic patients with atherosclerosis aged 35 years or older without clinical proteinuria, heart failure, or low ejection fraction (<40%), who were not taking ACE inhibitors or (ARB), were randomized into two groups to receive treatment with ramipril (ACEI group, beginning with 2.5 mg/d till reaching 5 mg/d) or placebo for 3 months. The 99 patients in ACEI group were further divided into 3 subgroups according to ACE (I/D) genotypes DD, ID and II, each group consisting of at least 20 patients. The level of hsCRP was detected by enzyme-linked immunosorbent assay before and after the therapy.


CONCLUSIONS
After therapy, hsCRP level significantly decreased, but hsCRP levels showed no significant differences between the groups of different ACE genotypes.
Wang
Ling
L
Institute of Cardiovascular Diseases of Guangdong Province, Guangzhou 510100, China. doctorwangling@21cn.com
Zhou
Ying-ling
YL
Lin
Shu-guang
SG
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000150:complications / Q000201:enzymology*; D002097:C-Reactive Protein / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000201:enzymology*; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000235:genetics*; D011110:Polymorphism, Genetic; D017257:Ramipril / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D002097:C-Reactive Protein; D007703:Peptidyl-Dipeptidase A; D017257:Ramipril